Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
前日終値
$400.71
+$9.92 · +2.54%
市場前
$401.5
+$0.79 · +0.20%
10月12日 7:07 ET
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
65
割安
センチメント
47
まちまち
リスク
43
やや高いリスク
モメンタム
69
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
日中レンジ
現在 $400.71
52週レンジ
現在 $400.71
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 23.06億 USD | 16.97億 USD | 10.83億 USD | 8.2億 USD | 6.25億 USD |
| 売上原価 | 8.11億 USD | 6.74億 USD | 5.9億 USD | 4.56億 USD | 3.18億 USD |
| 粗利益 | 14.95億 USD | 10.23億 USD | 4.93億 USD | 3.64億 USD | 3.07億 USD |
| 研究開発 | 6.24億 USD | 4.04億 USD | 3.21億 USD | 3.16億 USD | 2.64億 USD |
| 販売・一般管理 | 11.77億 USD | 8.41億 USD | 6.18億 USD | 5.89億 USD | 5.11億 USD |
| 営業費用 | 18.05億 USD | 12.45億 USD | 9.39億 USD | 9.05億 USD | 7.75億 USD |
| 受取利息 | 4589.1万 USD | 4324.8万 USD | 2435.3万 USD | 353.8万 USD | 538.1万 USD |
| 支払利息 | 406.9万 USD | 1068.5万 USD | 1263.8万 USD | 931.9万 USD | 830.5万 USD |
| 減価償却費と償却費 | 4348.4万 USD | 3096.8万 USD | 2409.7万 USD | 1670.2万 USD | 1125.4万 USD |
| 営業利益 | −3.1億 USD | −2.22億 USD | −4.46億 USD | −5.41億 USD | −4.68億 USD |
| 純利益 | −2.08億 USD | −1.9億 USD | −4.35億 USD | −5.48億 USD | −4.72億 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$359.07
下落余地(10.39%)この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI13.92億0.06%2.3兆 USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB10.08億0.54%1853億 USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK5.78億1.26%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF5.36億0.55%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB4.08億3.88%108.2億 USD0.44%$206.49+3.00%
iShares Russell Mid-Cap Growth ETFIWP3.01億1.52%200.95億 USD0.23%$143.1+1.56%
iShares Russell Mid-Cap ETFIWR2.22億0.39%567.65億 USD0.18%$109.82+0.87%
iShares Russell 1000 Growth ETFIWF2億0.15%1305.08億 USD0.18%$127.91+0.63%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
iShares Biotechnology ETFIBB
iShares Russell Mid-Cap Growth ETFIWP
iShares Russell Mid-Cap ETFIWR
iShares Russell 1000 Growth ETFIWFAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。